In boyhood, the human growth hormone (GH) controls a young man's height. Its value lies in creating an optimized physiological environment where muscle growth happens more efficiently — better recovery, deeper sleep, improved body composition, and healthier connective tissue. Growth hormone’s real strengths in a performance context are recovery, fat metabolism, sleep quality, and connective tissue repair. One of the most debated claims in the fitness world is whether growth hormone (GH) actually builds muscle.
Testosterone production is heavily dependent on sleep quality — particularly deep sleep. GH and IGF-1 play supporting roles in androgen metabolism and body composition. That said, the indirect effects are real and worth understanding. It doesn't stimulate LH, FSH, or testicular testosterone production. The before and after at 6 months looks different from the before and after at 6 weeks, and that gap is enormous. Six months in, the cumulative effects of sustained GH/IGF-1 elevation are measurable. If you've combined ipamorelin with consistent training and reasonable nutrition, this is where the "before and after" difference becomes clear enough to photograph.
In three, 2–9 week randomized, double-blind, placebo-controlled clinical studies examining the effects of ibutamoren on serum IGF-1 levels and markers of bone turnover in 187 elderly adults, treatment was well tolerated, with no serious drug-related AEs observed in patients on ibutamoren. The authors observed that sermorelin led to significant increases in GH release for the 2 h after administration and the 12-h mean GH levels at both 4 week and 16 weeks of treatment compared to placebo for both genders. Although body weight, body fat, and testosterone levels were unchanged, these findings demonstrate the potential for sermorelin as adjunctive or alternative therapy in hypogonadal men, and further highlight the need for additional long-term studies. The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. Kingdom (trtkingdom.com) is a physician-supervised telehealth platform offering compounded Sermorelin therapy with a men's trt + sermorelin optimization platform approach to growth hormone optimization. An ipamorelin stacking guide outlines how to combine ipamorelin with other growth hormone-releasing peptides to amplify pulsatile GH secretion through complementary receptor pathways. The peptide works by mimicking ghrelin's binding to growth hormone secretagogue receptor 1a (GHS-R1a) in the anterior pituitary, triggering a pulsatile release that mirrors natural circadian patterns.
Gelander et al. evaluated the short-term effects of 1 mg sermorelin and GHRH 1–40 injections on GH, IGF-1, prolactin, follicle-stimulating hormone (FSH), and LH levels in short children with pulsatile GH secretion (25). As a result of these controversies and limitations, a new class of drugs known as growth hormone secretagogues (GHS) (Table 1) has emerged as a potential alternative to GH therapy. In a recent meta-analysis of 16 trials of hypogonadal men receiving TTh, Guo et al. found that although TTh led to increased lean body mass and a reduction in total cholesterol levels, the observed decrease in fat mass was not significant. Partially in response to this, growth hormone secretagogues (GHS) have emerged as a potential novel adjunctive therapy for some of the symptoms of hypogonadism, although current data on their clinical efficacy largely remain lacking.
Dosing typically involves 1 mg tesamorelin with 200 mcg ipamorelin once daily, administered subcutaneously before the first meal of the day to maximize fat oxidation during the fasted state. That said, some advanced research models use low-dose MK-677 (ibutamoren), an oral ghrelin mimetic, alongside ipamorelin. Blocking or reducing somatostatin activity can theoretically amplify ipamorelin's effect by removing the inhibitory signal that would otherwise suppress GH release. Research protocols using hexarelin limit administration to 4–6 weeks maximum and often pair it with ipamorelin at a lower dose to sustain baseline GH support while hexarelin drives peak pulses.
Rather, GHSs bind a receptor (GHS-R) that is coupled via members of the Gq/i family of proteins and that activates phospholipase C(24, 26). The first GHRP with significant in vivo activity was a hexapeptide, His-DTrp-Ala-Trp-DPhe-LysNH2, also known as GHRP-6.(24, 25) Despite mimicking natural GHRH action, GHRPs do not bind the seven-transmembrane domain, G protein-coupled GHRH receptor (GHRH-R), which functions via the protein kinase A pathway. The first peptide that was found to stimulate GH release from rat pituitary cells was Tyr-DTrp2-Gly-Phe-MetNH2.
More significant increases in IGF-1 levels were observed in the ibutamoren group when compared with placebo (84% vs. 17%, respectively). To date, few long-term, rigorously controlled studies have examined the efficacy and safety of GHSs, although GHSs may improve growth velocity in children, stimulate appetite, improve lean mass in wasting states and in obese individuals, reduce bone turnover, increase fat-free mass, and improve sleep. Growth hormone (GH) increases lean body mass, reduces fat mass, increases exercise tolerance and maximum oxygen uptake, enhances muscle strength, and improves linear growth.
The study measured multiple serum hormone values throughout the treatment period while also assessing changes in the GH release waveform induced by GHRH vs. GHRP-2. These results highlight that, compared to the short-term treatment in the Vittone study, longer term treatment with sermorelin results in increases in GH and IGF-1 in addition to changes in body composition seen with increased lean body mass. For men, no changes in testosterone levels were observed but a significant increase in insulin sensitivity was noted along with improvements in wellbeing and libido. IGF-1 levels rose significantly by 2 weeks of treatment and remained elevated until 12 weeks before declining at 16 weeks. Ten women and nine men between 55 and 71 years old were administered 4 weeks of nightly subcutaneous placebo followed by 16 weeks of 10 µg/kg of sermorelin.
TRT, anabolic steroids, and exogenous growth hormone are clearly in the enhanced zone because they replace your natural production and suppress your endogenous systems. MK-677 and growth hormone secretagogues sit in a similar natty plus zone for the GH axis. At the other end you have high-dose multi-compound cycles of anabolic steroids, insulin, and growth hormone. Sermorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) — the naturally occurring peptide produced in the hypothalamus that signals the pituitary gland to secrete growth hormone (GH). These compounds can be run concurrently with an ipamorelin stack without receptor competition, but they do not amplify GH release or IGF-1 production. No, ipamorelin has high selectivity for GHS-R1a receptors and does not activate the acetylcholine or dopamine pathways that trigger cortisol or prolactin release.